$ROIV · Roivant Sciences Ltd.
Roivant's Q2 FY2026 (ended September 30, 2026) 10-Q shows revenue of $35.1M, up 2135.6% YoY, driven by $31.0M in net product revenue from LISRAYA's first 5 weeks of launch following August 2026 FDA approval. Net loss attributable to Roivant was $191.6M (GAAP EPS -$0.27), versus $113.5M a year earlier, with operating margin at -763.2%. Cash, equivalents and marketable securities totaled $4.2B at quarter-end.
- Product revenue of $31.0M came entirely from LISRAYA's first 5 weeks of launch after August 2026 FDA approval.
- Total revenue of $35.1M rose 2135.6% YoY from $1.6M.
- Net loss attributable to Roivant widened to $191.6M from $113.5M a year earlier.
- GAAP EPS was -$0.27 with operating margin of -763.2%.
- Cash, equivalents and marketable securities totaled $4.2B at September 30, 2026.
Extended-hours last trade of $40.26 is +3.55% vs the $38.88 regular close, suggesting a positive initial reaction to the LISRAYA launch revenue. Regular session closed +6.17% on the day.
Roivant's first commercial product launch (LISRAYA) generated $31M in its first five weeks, validating the company's transition to a revenue-generating biotech.
The LISRAYA launch marks Roivant's transition from clinical-stage to commercial-stage biotech, a key inflection for the Vant model.
R&D and SG&A expenses remain elevated ($303.2M total operating expenses in the quarter), and the company expects to continue incurring significant operating losses for the foreseeable future.